Category News

AliveGen Reports ALG-801 Outperforms Standard

AliveGen Reports ALG-801 Outperforms Standard Therapies in PAH Model

AliveGen USA Inc. (AliveGen), a clinical-stage biopharmaceutical company focused on developing novel therapies for serious cardiopulmonary diseases, today announced compelling new preclinical results for its investigational therapy ALG-801. The data show that ALG-801 delivered superior efficacy compared with current standard-of-care…

Read MoreAliveGen Reports ALG-801 Outperforms Standard Therapies in PAH Model